<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35532120</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1521-0464</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery</Title>
          <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>GSDMD-dependent pyroptotic induction by a multivalent CXCR4-targeted nanotoxin blocks colorectal cancer metastases.</ArticleTitle>
        <Pagination>
          <StartPage>1384</StartPage>
          <EndPage>1397</EndPage>
          <MedlinePgn>1384-1397</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10717544.2022.2069302</ELocationID>
        <Abstract>
          <AbstractText>Colorectal cancer (CRC) remains the third cause of cancer-related mortality in Western countries, metastases are the main cause of death. CRC treatment remains limited by systemic toxicity and chemotherapy resistance. Therefore, nanoparticle-mediated delivery of cytotoxic agents selectively to cancer cells represents an efficient strategy to increase the therapeutic index and overcome drug resistance. We have developed the T22-PE24-H6 therapeutic protein-only nanoparticle that incorporates the exotoxin A from <i>Pseudomonas aeruginosa</i> to selectively target CRC cells because of its multivalent ligand display that triggers a high selectivity interaction with the CXCR4 receptor overexpressed on the surface of CRC stem cells. We here observed a CXCR4-dependent cytotoxic effect for T22-PE24-H6, which was not mediated by apoptosis, but instead capable of inducing a time-dependent and sequential activation of pyroptotic markers in CRC cells <i>in vitro</i>. Next, we demonstrated that repeated doses of T22-PE24-H6 inhibit tumor growth in a subcutaneous CXCR4<sup>+</sup> CRC model, also through pyroptotic activation. Most importantly, this nanoparticle also blocked the development of lymphatic and hematogenous metastases, in a highly aggressive CXCR4<sup>+</sup> SW1417 orthotopic CRC model, in the absence of systemic toxicity. This targeted drug delivery approach supports for the first time the clinical relevance of inducing GSDMD-dependent pyroptosis, a cell death mechanism alternative to apoptosis, in CRC models, leading to the selective elimination of CXCR4<sup>+</sup> cancer stem cells, which are associated with resistance, metastases and anti-apoptotic upregulation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sala</LastName>
            <ForeName>Rita</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Institute Sant Pau (IIB-Sant Pau), Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>CIBER en Bioingeniería, Biomateriales Y Nanomedicina (CIBER-BBN), Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Josep Carreras Research Institute, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rioja-Blanco</LastName>
            <ForeName>Elisa</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Institute Sant Pau (IIB-Sant Pau), Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Josep Carreras Research Institute, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Serna</LastName>
            <ForeName>Naroa</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>CIBER en Bioingeniería, Biomateriales Y Nanomedicina (CIBER-BBN), Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institut de Biotecnologia I de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Departament de Genètica I de Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sánchez-García</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>CIBER en Bioingeniería, Biomateriales Y Nanomedicina (CIBER-BBN), Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institut de Biotecnologia I de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Departament de Genètica I de Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Álamo</LastName>
            <ForeName>Patricia</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Institute Sant Pau (IIB-Sant Pau), Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>CIBER en Bioingeniería, Biomateriales Y Nanomedicina (CIBER-BBN), Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Josep Carreras Research Institute, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alba-Castellón</LastName>
            <ForeName>Lorena</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Institute Sant Pau (IIB-Sant Pau), Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Josep Carreras Research Institute, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Casanova</LastName>
            <ForeName>Isolda</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Institute Sant Pau (IIB-Sant Pau), Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>CIBER en Bioingeniería, Biomateriales Y Nanomedicina (CIBER-BBN), Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Josep Carreras Research Institute, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>López-Pousa</LastName>
            <ForeName>Antonio</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>CIBER en Bioingeniería, Biomateriales Y Nanomedicina (CIBER-BBN), Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Hospital de la Santa Creu I Sant Pau, Barcelon, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Unzueta</LastName>
            <ForeName>Ugutz</ForeName>
            <Initials>U</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Institute Sant Pau (IIB-Sant Pau), Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>CIBER en Bioingeniería, Biomateriales Y Nanomedicina (CIBER-BBN), Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Josep Carreras Research Institute, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Céspedes</LastName>
            <ForeName>María Virtudes</ForeName>
            <Initials>MV</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Institute Sant Pau (IIB-Sant Pau), Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vázquez</LastName>
            <ForeName>Esther</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>CIBER en Bioingeniería, Biomateriales Y Nanomedicina (CIBER-BBN), Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institut de Biotecnologia I de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Departament de Genètica I de Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Villaverde</LastName>
            <ForeName>Antonio</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>CIBER en Bioingeniería, Biomateriales Y Nanomedicina (CIBER-BBN), Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institut de Biotecnologia I de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Departament de Genètica I de Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mangues</LastName>
            <ForeName>Ramon</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Institute Sant Pau (IIB-Sant Pau), Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>CIBER en Bioingeniería, Biomateriales Y Nanomedicina (CIBER-BBN), Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Josep Carreras Research Institute, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Deliv</MedlineTA>
        <NlmUniqueID>9417471</NlmUniqueID>
        <ISSNLinking>1071-7544</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C527276">CXCR4 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C498366">GSDMD protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D028044">Phosphate-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D052899">Pore Forming Cytotoxic Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019718">Receptors, CXCR4</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="Y">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D028044" MajorTopicYN="Y">Phosphate-Binding Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D052899" MajorTopicYN="Y">Pore Forming Cytotoxic Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069292" MajorTopicYN="Y">Pyroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019718" MajorTopicYN="Y">Receptors, CXCR4</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CXCR4</Keyword>
        <Keyword MajorTopicYN="N">GSDMD</Keyword>
        <Keyword MajorTopicYN="N">Metastasis</Keyword>
        <Keyword MajorTopicYN="N">PE24 exotoxin</Keyword>
        <Keyword MajorTopicYN="N">colorectal cancer</Keyword>
        <Keyword MajorTopicYN="N">pyroptosis</Keyword>
        <Keyword MajorTopicYN="N">targeted nanoparticle</Keyword>
      </KeywordList>
      <CoiStatement>AV, EV, UU, RM, IC are cited as inventors in three patents: PCT/EP2018/061732, covering Nanostructured Proteins and uses thereof; PCT/EP2018/069303, covering Therapeutic Nanoconjugates and uses thereof; and PCT/EP2012/050513 (WO2012/095527), covering Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells, all licensed to Nanoligent. AV, EV, RM are scientific advisors and cofounders of Nanoligent. The authors report no other conflicts of interest in this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>9</Day>
          <Hour>7</Hour>
          <Minute>53</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35532120</ArticleId>
        <ArticleId IdType="pmc">PMC9090371</ArticleId>
        <ArticleId IdType="doi">10.1080/10717544.2022.2069302</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Aizawa E, Karasawa T, Watanabe S, et al.  (2020.  May 22). GSDME-dependent incomplete pyroptosis permits selective IL-1α release under caspase-1 inhibition. iScience
23:101070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7200307</ArticleId>
            <ArticleId IdType="pubmed">32361594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Céspedes MV, Espina C, García-Cabezas MA, et al.  (2007). Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am J Pathol
170:1077–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1864873</ArticleId>
            <ArticleId IdType="pubmed">17322390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Céspedes MV, Unzueta U, Álamo P, et al.  (2016). Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4+ colorectal cancer models. Nanomedicine
12:1987–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27085904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Céspedes MV, Unzueta U, Aviñó A, et al.  (2018). Selective depletion of metastatic stem cells as therapy for human colorectal cancer. EMBO Mol Med
10:e8772 (1-22).</Citation>
        </Reference>
        <Reference>
          <Citation>Crooke H, Kobayashi M, Mitchell B, et al.  (2018). Estimating 1- and 5-year relative survival trends in colorectal cancer (CRC) in the United States: 2004 to 2014. JCO
36:587.</Citation>
        </Reference>
        <Reference>
          <Citation>Falgàs A, Pallarès V, Serna N, et al.  (2020). Selective delivery of T22-PE24-H6 to CXCR4+ diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model. Theranostics
10:5169–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7196303</ArticleId>
            <ArticleId IdType="pubmed">32373205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Falgàs A, Pallarès V, Unzueta U, et al.  (2020). A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models. Haematologica
105:741–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7049335</ArticleId>
            <ArticleId IdType="pubmed">31248974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Francipane MG, Bulanin D, Lagasse E. (2019). Establishment and characterization of 5-fluorouracil-resistant human colorectal cancer stem-like cells: tumor dynamics under selection pressure. Int J Mol Sci
20:1817 (1-23).</Citation>
        </Reference>
        <Reference>
          <Citation>Geng M, Wang L, Li P. (2013.  Oct 15). Correlation between chemosensitivity to anticancer drugs and Bcl-2 expression in gastric cancer. Int J Clin Exp Pathol
6:2554–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3816827</ArticleId>
            <ArticleId IdType="pubmed">24228120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldsmith KC, Gross M, Peirce S, et al.  (2012.  May 15). Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma. Cancer Res
72:2565–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3354953</ArticleId>
            <ArticleId IdType="pubmed">22589275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D, Weinberg RA. (2011). Hallmarks of cancer: the next generation. Cell
144:646–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21376230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayward RL, Macpherson JS, Cummings J, et al.  Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect. Mol Cancer Ther 3(2):169–78.</Citation>
        </Reference>
        <Reference>
          <Citation>Jorgensen I, Miao EA. (2015.  May). Pyroptotic cell death defends against intracellular pathogens. Immunol Rev
265:130–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4400865</ArticleId>
            <ArticleId IdType="pubmed">25879289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J, Takeuchi H, Lam ST, et al.  (2005). Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. JCO
23:2744–53.</Citation>
        </Reference>
        <Reference>
          <Citation>Kim J-S, Jun S-Y, Kim Y-S. (2020). Critical issues in the development of immunotoxins for anticancer therapy. J Pharm Sci
109:104–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31669121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kreitman RJ, Tallman MS, Robak T, et al.  (2012.  May 20). Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol
30:1822–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3383181</ArticleId>
            <ArticleId IdType="pubmed">22355053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu M, Apriceno A, Sipin M, et al.  (2020). Combinatorial entropy behaviour leads to range selective binding in ligand-receptor interactions. Nat Commun
11:4836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7515919</ArticleId>
            <ArticleId IdType="pubmed">32973157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez-Veracoechea FJ, Frenkel D. (2011). Designing super selectivity in multivalent nano-particle binding. Proc Natl Acad Sci USA
108:10963–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3131366</ArticleId>
            <ArticleId IdType="pubmed">21690358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mulvihill E, Sborgi L, Mari SA, et al.  (2018). Mechanism of membrane pore formation by human gasdermin‐D. Embo J
37(14):e98321 (1-11).</Citation>
        </Reference>
        <Reference>
          <Citation>Nagarajan K, Soundarapandian K, Thorne RF, et al.  (2019). Activation of pyroptotic cell death pathways in cancer: an alternative therapeutic approach. Transl Oncol
12:925–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6518321</ArticleId>
            <ArticleId IdType="pubmed">31085408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onda M, Beers R, Xiang L, et al.  (2011). Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci USA
108:5742–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3078343</ArticleId>
            <ArticleId IdType="pubmed">21436054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pallarès V, Unzueta U, Falgàs A, et al.  (2020). An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination. J Hematol Oncol
13:36 (1-19).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7160905</ArticleId>
            <ArticleId IdType="pubmed">32295630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan S-T, Li Z-L, He Z-X, et al.  (2016). Molecular mechanisms for tumour resistance to chemotherapy. Clin Exp Pharmacol Physiol
43:723–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27097837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rioja-Blanco E, Arroyo-Solera I, Álamo P, et al.  (2022). CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma. J Exp Clin Cancer Res
41:49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8815235</ArticleId>
            <ArticleId IdType="pubmed">35120582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rueda F, Céspedes MV, Conchillo‐Solé O, et al.  (2015). Bottom-up instructive quality control in the biofabrication of smart protein materials. Adv Mater
27:7816–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26509451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sánchez-García L, Serna N, Álamo P, et al.  (2018). Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs. J Control Release
274:81–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29408658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schulze-Bergkamen H, Ehrenberg R, Hickmann L, et al.  (2008). Bcl-x(L) and myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells. World J Gastroenterol
14:3829–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2721439</ArticleId>
            <ArticleId IdType="pubmed">18609706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serna N, Álamo P, Ramesh P, et al.  (2020). Nanostructured toxins for the selective destruction of drug-resistant human CXCR4+ colorectal cancer stem cells. J Control Release
320:96–104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31931052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shan L, Liu Y, Wang P. (2013). Recombinant immunotoxin therapy of solid tumors: challenges and strategies. J Basic Clin Med
2:1–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4192646</ArticleId>
            <ArticleId IdType="pubmed">25309827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma A, Madhunapantula SV, Robertson GP. (2012). Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems
Expert Opin Drug Metab Toxicol
8:47–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3245366</ArticleId>
            <ArticleId IdType="pubmed">22097965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh R, Lillard JW. (2009). Nanoparticle-based targeted drug delivery. Exp Mol Pathol
86:215–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3249419</ArticleId>
            <ArticleId IdType="pubmed">19186176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song X, Shen L, Tong J, et al.  (2020). Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer. Theranostics
10:8098–110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7381732</ArticleId>
            <ArticleId IdType="pubmed">32724460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tait SWG, Ichim G, Green DR. (2014). Die another way-non-apoptotic mechanisms of cell death. J Cell Sci
127:2135–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4021468</ArticleId>
            <ArticleId IdType="pubmed">24833670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Touil Y, Igoudjil W, Corvaisier M, et al.  (2014). Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Clin Cancer Res
20:837–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4387277</ArticleId>
            <ArticleId IdType="pubmed">24323901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Virag P, Fischer-Fodor E, Perde-Schrepler M, et al.  (2013). Oxaliplatin induces different cellular and molecular chemoresistance patterns in colorectal cancer cell lines of identical origins. BMC Genomics
14:480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3776436</ArticleId>
            <ArticleId IdType="pubmed">23865481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Gao W, Shi X, et al.  (2017). Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature
547:99–103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28459430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weldon JE, Pastan I. (2011). A guide to taming a toxin-recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. Febs J
278:4683–700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3179548</ArticleId>
            <ArticleId IdType="pubmed">21585657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson TR, Longley DB, Johnston PG. (2006). Chemoresistance in solid tumours. Ann Oncol
17(Suppl 10):x315–324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17018746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Z-Y, Tang J-N, Xie H-X, et al.  (2015). 5-Fluorouracil chemotherapy of gastric cancer generates residual cells with properties of cancer stem cells. Int J Biol Sci
11:284–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4323368</ArticleId>
            <ArticleId IdType="pubmed">25678847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang X, Zheng F, Xing H, et al.  (2004). Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer. J Cancer Res Clin Oncol
130:423–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15156398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yip KW, Reed JC. (2008). Bcl-2 family proteins and cancer. Oncogene
27:6398–406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18955968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Yu J, Park BH, et al.  (2000). Role of BAX in the apoptotic response to anticancer agents. Science
290:989–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11062132</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
